We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nuclear Transplantation Corrects Immune Deficiency

By Biotechdaily staff writers
Posted on 22 May 2002
A mouse model has been used to establish for the first time that a combination of nuclear transplantation, gene therapy, and embryonic stem cell differentiation can be used to create custom-tailored cellular therapies for genetic disorders such as immune deficiency.
The research was conducted at the Whitehead Institute (Cambridge, MA, USA) and was posted on the Cell website on March 8, 2002. More...


Scientists have been able to use nuclear transfer to create embryonic stem cells and differentiate them in culture to create many different cell types, including muscle, neurons, and hematopoietic stem cells, which are precursors to all immune and blood cells. However, they have never shown that the cells created in culture could be reintroduced into an animal to treat a disease.

In the current study, skin cells from a mouse, which was completely immune deficient, were used to create a cellular therapy that was able to partially restore immune function in the mouse. The nucleus was removed from an egg and replaced with the nucleus from a skin cell of an adult mouse with a genetic immune deficiency. In this procedure, the egg resets the developmental clock of the adult nucleus, and the reprogrammed cell starts developing into an embryo that is genetically identical to the donor cell. "Though the immune system was not completely restored, there was enough improvement to predict that a comparable result in humans would translate into a significant clinical benefit, says George Daley, head of one research team.

"This is a proof-of-principle experiment, which shows that nuclear transplantation therapy may be possible for human application. Furthermore, it shows that gene therapy can be incorporated into the approach to correct genetic mutations in defective cells without affecting the germ line,” added Rudolph Jaenisch, head of the other research team. "While these results show nuclear transplantation therapy can work in principle, there are technical issues that we are working on now.”




Related Links:
Whitehead Institute

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.